Dual‑acting quinazolinone antiviral targeting ZIKV and DENV

SI-8155

Dual‑acting quinazolinone antiviral targeting ZIKV and DENV, >98% (HPLC)

IUPAC Name : (E)-3-(3-(Tert-butyl)phenyl)-2-(2-(6-methoxypyridin-2-yl)vinyl)-6-(piperidin-1-yl)quinazolin-4(3H)-one

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is a 2,3,6‑trisubstituted quinazolinone antiviral identified through phenotypic screening as a potent inhibitor of Zika (ZIKV) and dengue (DENV) virus replication. It shows broad dual‑virus activity with EC₅₀ values down to 86 nM and no significant cytotoxicity to mammalian cells, making it a promising small‑molecule lead for ZIKV/DENV antiviral development.

References : Md Ashraf-Uz-Zaman et al.: J. Med. Chem., 66(15), 10746-10760, 2023.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.